Sartorius Stedim Biotech acquires Cellca

3 July 2015

France-headquartered Sartorius Stedim Biotech (SSB), a leading international supplier for the pharma and biotech industries, has acquired Cellca GmbH based in Laupheim, Germany.

Founded in 2005, the company with around 30 employees generated sales revenue of around 6 million euros ($6.7 million) in 2014. Financial terms of the transaction were not disclosed.

Cellca’s major customers are biopharmaceutical companies as well as biosimilar firms that do not, or only partly, conduct their process development in their in-house facilities. Through this acquisition, Sartorius Stedim Biotech is further expanding its service offering for process development. SSB has already strengthened this segment by its two recent acquisitions of BioOutsource and TAP Biosystems.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK